|1.||Yang, Ximing J: 9 articles (12/2006 - 06/2002)|
|2.||Wanders, Ronald J A: 8 articles (02/2015 - 11/2005)|
|3.||Buckel, Wolfgang: 8 articles (02/2015 - 04/2002)|
|4.||Pallottini, Valentina: 7 articles (11/2011 - 08/2005)|
|5.||Cheng, Liang: 7 articles (01/2011 - 09/2004)|
|6.||Liao, James K: 7 articles (05/2010 - 11/2002)|
|7.||Fukao, Toshiyuki: 6 articles (02/2015 - 12/2004)|
|8.||Davidson, Michael H: 6 articles (01/2009 - 01/2003)|
|9.||Jiang, Zhong: 6 articles (01/2009 - 06/2002)|
|10.||Humphrey, Peter A: 5 articles (07/2014 - 09/2004)|
09/01/2002 - "Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) have been demonstrated to be very effective in the treatment of patients with hypercholesterolemia where they reduce the rate of coronary and cerebrovascular complications. "
10/01/2010 - "3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are a common and effective treatment for hypercholesterolemia, with a low overall rate of side-effects. "
05/08/2008 - "3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGR) inhibitors, more commonly known as statins, represent the gold standard in treating hypercholesterolemia. "
05/01/1994 - "Based on recent studies suggesting that low doses of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors are safe and effective, these agents have emerged as the drugs of first choice in the pharmacologic treatment of posttransplant hypercholesterolemia. "
12/01/2005 - "Therapy with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) is the first-line treatment option for hypercholesterolemia, and observational studies have suggested that the risk of AD is reduced in patients who receive statin therapy in midlife. "
04/19/2013 - "Our findings demonstrate that COA-Cl exerts both neuroprotective and neurorestorative effects over a broad therapeutic time window, suggesting COA-Cl might be a novel and potent therapeutic agent for ischemic stroke."
01/01/2013 - "These cases help us to pay attention to the possibility of CoA in adolescents with hypertensive stroke. "
11/10/2011 - "The results show that LV stroke work varies from 0.98J (no-AS; no-COA) up to 2.15J (AS: 0.61cm(2)+COA: 90%). "
02/20/2003 - "However, recent secondary prevention studies with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have demonstrated a significant reduction in ischemic stroke without an increase in hemorrhagic stroke. "
01/01/2003 - "Recent clinical studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) exert protective effects against nonhemorrhagic stroke. "
|3.||Cardiovascular Diseases (Cardiovascular Disease)
02/01/2015 - "Despite the importance of patients' adherence to their drug treatments for achieving desired therapeutic goals and the proven role 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) for the health status of patients with cardiovascular diseases, there is not enough information regarding diabetic patients' adherence to statin therapy in developing countries. "
04/06/2009 - "Among 229 patients operated for CoA in Aarhus between 1965 and 1985, 14 died at surgery and 35 died during 20-40 years of follow-up, mainly due to cardiovascular disease. "
09/01/2006 - "An online survey, Care of the Older Adult with Cardiovascular Disease (COA-CVD), was used to describe self-rated competency in the care of the aging adult with cardiovascular disease and subsequently determine the future education and programming needs of the Council of Cardiovascular Nursing. "
01/01/2012 - "Large population-based studies have found elevated rates of cardiovascular disease, six cancers, liver and respiratory disease, and all-cause mortality in COA. "
03/01/2007 - "Lipid lowering with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or 'statins' has dramatically reduced morbidity and mortality in patients with established cardiovascular disease. "
01/01/2014 - "A total of 304 patients with mixed hyperlipidemia were randomized to receive CoA 400 U/d plus statin or placebo plus statin (n = 152, each group). "
11/01/2003 - "LCPUFAs are useful in the management of hyperlipidemia, inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, and may mediate the beneficial actions of statins. "
11/01/2003 - "Statin therapy (3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor) is beneficial for primary prevention of cardiovascular events in patients younger than age 65 years with hyperlipidemia, yet there is uncertainty about using these agents for primary prevention in octogenarians. "
06/01/2015 - "These results demonstrate that CoA plus statin therapy was more effective in improving lipoprotein parameters than statin alone in patients with metabolic syndrome and mixed hyperlipidemia."
09/01/2005 - "The introduction of various classes of lipid-lowering drugs, especially the hydroxymethylglutaryl-coenzyme-A-reductase inhibitors (statins), has allowed for effective treatment of hyperlipidemia. "
06/01/2015 - "Efficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia."
01/01/2014 - "Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study."
02/01/2013 - "CoA can effectively reduce plasma TG levels in subjects with moderate dyslipidemia and has no obvious adverse effect."
12/30/1975 - "[Coenzyme A and dyslipidemia. "
12/30/1975 - "[Coenzyme A and dyslipidemia. "
|2.||Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
|4.||Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)
|8.||Fibric Acids (Fibrates)
|10.||Coenzyme A (CoA)
|3.||Drug Therapy (Chemotherapy)
|4.||Blood Component Removal (Apheresis)
|5.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)